A recently developed electrode technology from NeuroOne (OTCQB:NMTC) offers new opportunities for neurological diagnostic and therapeutic solutions, particularly in brain and spine applications. The technology – the Evo™ Cortical Electrode1 (Evo)– is the first FDA-510(k) cleared thin film flexible electrode for recording, monitoring and stimulation of brain tissue for up to 30 days of use.
The technical features of this new electrode offer several advantages over other commercially available electrodes. Three key features of this technological innovation in electrocorticography are highlighted below.
Decreased Immunological Response
The Evo Cortical Electrode is over 7 times thinner and 8 times lighter than a silicone electrode. The flexibility and reduced volume should reduce pain and edema.
Video Link: https://www.youtube.com/embed/mtUw5KdqYO0
Single Tail Design
The single thin tail design allows the implanted electrode tail to be tunneled through one incision which should reduce infection risk and procedure time.
Reduced Cable Management
A disposable cable assembly is sent with each Evo Cortical Electrode as an electrode kit, which should remove the need to source the correct cables for each electrode being used in surgery. This is also expected to free hospital resources from the management of sterilizing and storing individual electrode cable assemblies.
Evo’s polyimide thin film technology should also provide an effective way to increase mechanical flexibility and reduce mass. This is better for the brain because these electrodes weigh less than traditional silicone electrodes and conform more completely to the brain to optimize contact. Also contacts on the electrodes may be scaled down in size, which is expected to improve the ability to increase recording resolutions, and electrode configurations are customizable to meet physician requests.
An expansion of Evo’s thin film platform, NeuroOne’s sEEG depth electrode is expected to offer advantages that include the ability to access deep cortical structures (where the cortical electrodes are placed on the brain’s surface) and implantation through tiny twist holes instead of a craniotomy. This less invasive implant procedures is expected to lead to fewer complications, less post-operative pain and shorter length of stay in the hospital.
1. Rx Only
PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures